NCT05624723

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis

A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years – 82 Years
• Healthy volunteers: Accepted

Summary

This is a multi-center, open-label, parallel-group study to evaluate oral doses of INCB054707 in participants with varying levels of renal function or impairment.

Conditions

• Renal Insufficiency
• Kidney Diseases

Interventions

Type	Name	Description
DRUG	INCB054707	INCB054707 75 mg will be administered orally

Timeline

• Start date: 2023-01-12
• Primary completion: 2024-02-07
• Completion: 2024-02-07
• First posted: 2022-11-22
• Last updated: 2024-02-13

Locations

2 sites across 2 countries: United States, Germany

Regulatory

• FDA-regulated drug study